BTIG lowered the firm’s price target on Precision BioSciences to $2 from $6 and keeps a Buy rating on the shares. The firm adjusts its model to push out its assumed U.S. market launch of Azer-cel to 2027 and EU launch to 2028, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>